COMMUNIQUÉS West-GlobeNewswire

Transactions under Novonesis’ share buyback program
26/10/2026
Please read the announcement in PDF Attachment 2026_25_Share_buyback
Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026
26/10/2026
REDWOOD CITY, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc . (Nasdaq: CHRS), today announced that its third quarter 2026 financial results will be released on Monday, November 9, 2026. Starting at 5: [...]
Kraig Labs Moves Beyond Bold Breakthrough
26/10/2026
DENVER, Oct. 26, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com ) — Kraig Biocraft Laboratories (OTCQB: KBLB) is moving beyond the science of spider silk and into the business of making it matter. For years, commercial [...]
Newsweek Places KFSH in Top 4% of World’s Smart Hospitals for Digital Maturity and AI
26/10/2026
RIYADH, Saudi Arabia, Oct. 26, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSH) is one of only 15 hospitals worldwide to receive both the maximum five-ribbon digital maturity rating [...]
CasZyme and Cirena to Collaborate on Developing Longer Guide RNAs to Optimise Cas12l Performance
26/10/2026
- Collaboration will combine CasZyme’s Cas12l nuclease with Cirena’s RNA manufacturing excellence to optimise editing efficiency - Output of the collaboration could prove highly relevant in CAR-T and LNP-based [...]
BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer
26/10/2026
MAINZ, Germany and SHANGHAI, China, October 26, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and DualityBiologics (Suzhou) Co., Ltd. (“DualityBio”, HKEX: 9606.HK) announced today that the DYNASTY-Breast02 global Phase [...]
Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress
26/10/2026
TLR7/8 dual-agonist EIK1001 plus pembrolizumab and chemotherapy in first-line, stage 4 non-small cell lung cancer (NSCLC) demonstrates durable effect in combination with standard-of-care, and a tolerability profile [...]
Newsweek Places KFSH in Top 4% of World's Smart Hospitals for Digital Maturity and AI
26/10/2026
RIYADH, Saudi Arabia, Oct. 26, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSH) is one of only 15 hospitals worldwide to receive both the maximum five-ribbon digital maturity rating [...]
InnoCare Reports 2026 Q3 Results, Sustained Profitability and Accelerating Globalization
26/10/2026
BEIJING, Oct. 26, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced its third quarter 2026 results and [...]
Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
26/10/2026
Media Release COPENHAGEN, Denmark; October 26, 2026 Median overall survival (OS) outcomes and encouraging anti-tumor activity observed with petosemtamab plus pembrolizumab in first-line (1L) recurrent or metastatic PD- [...]
Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026
26/10/2026
Primary safety endpoint achieved; exploratory findings highlight encouraging survival outcomes in heavily pretreated patients One second-line patient achieved progression-free survival of 16.39 months and overall [...]
Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026
26/10/2026
Active LN patients in the Phase 1 study treated with FT819 and the less-intensive conditioning (bendamustine) regimen selected for the RECLAIM-LN study achieved 100% renal response at Month 6, with approximately 50% [...]
Pluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform for Regenerative Medicine
26/10/2026
Partnership combines Pluri’s proprietary cell technology and clinical-development experience with ZEO’s biologics manufacturing expertise, established physician network, and sales, marketing, and educational [...]
Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis
26/10/2026
61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose (600 mg) group, highly similar to EVERLAST-A Continued favorable safety and tolerability profile consistent with the IL-23p19 class ORKA-001 on track to advance [...]
BPGbio Presents Phase 2 Glioblastoma Data Update at ESMO Congress 2026, Highlighting Median Overall Survival of 19.9 Months in MGMT-Unmethylated Patients
26/10/2026
Median overall survival of 19.9 months in patients with MGMT-unmethylated glioblastoma compares favorably with historical outcomes BPM31510 demonstrated a well-tolerated safety profile in combination with standard-of- [...]
Eledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology Kidney Week 2026 Annual Meeting
26/10/2026
Tegoprubart-treated patients demonstrated a mean improvement on the total MTSOSD-59R symptom occurrence scale at 12 months while tacrolimus-treated patients experienced a mean worsening of symptom occurrence [...]
Harrow To Report Third Quarter 2026 Financial Results After Market Close on November 9, 2026
26/10/2026
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on November 10, 2026 NASHVILLE, Tenn., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease [...]
Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights
26/10/2026
Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in November 2026 IND filing for the Enhanced Brain Delivery™ (EBD ® ) [...]
VETmAb Biosciences Announces Positive Clinical Proof-of-Concept Results for Long-Acting Anti-IL-23 Antibody in Canine Chronic Inflammatory Enteropathy
26/10/2026
In the VMB-C001a group, 77.8% of dogs were considered a treatment success, compared with 30.0% in the placebo group VMB-C001a granted eligibility for the U.S. Food and Drug Administration’s (FDA) Center for Veterinary [...]

Pages